Speakers

Expand/Collapse

Joe Codamo
Senior Director
Catalent Pharma Solutions

Day 1 – Track C – Afternoon

2:00 pm | Flexible & Innovative Design Considerations for Cell Therapy Processes & Facilities

Patrick Melvin
VP, Clinical Development
Syneos Health

Jane Bentley
VP, Project Management
Syneos Health

Day 1 – Track B – Afternoon

3:00 pm | Next-Gen Cell Therapies- Listening and Engaging with Patient Perspectives as an Essential Element in Clinical Trials

Sharon Longhurst
VP Development
Gadeta

Day 1 – Track C – Afternoon

3:00 pm | Panel Discussion: Creating the Therapies of Tomorrow with Large Scale Production of Off-the-Shelf Products

Gabriel Gata
PhD, Field Application Scientist Lead
Lonza Personalized Medicine

Hemant Dhamne
Gene & Cell Therapy
Independent Expert

Day 2 - Track C - Morning

10:45 am | Smart Manufacturing Technologies for Cell & Gene Therapy Products

Dian Kortleve
Scientist
Pan Cancer T

Day 1 – Track A – Evening

5:30 pm | Identification & Testing of Novel Cancer-Restricted Targets & Their TCRS to Develop Safe & Effective T-Cell Treatment

Elie Haddad
Professor, Department of Pediatrics
University of Montreal

Focus Day - Track B - Morning

10:30 am | CAR Therapy Beyond T-Cells: CAR-NK Cells or Even CAR In Stem Cells for Cancer Immunotherapy?

John Rossi
Senior Vice President, Translational Medicines & Research
CERo Therapeutics

Day 1 – Track A – Afternoon

3:00 pm | Panel Discussion: Changing the Face of Cell Therapies with In Vivo Gene Engineering

Day One

Tuesday 25th February 2020

9:00 am | Industry Leaders’ Fireside Chat - Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches

Day Two

Wednesday 26th February 2020

8:15 am | Development & Functional Characterisation of Chimeric Engulfment Receptor (CER) T-Cells for the Treatment of Hematologic & Solid Malignancies

Reagan Jarvis
Chief Executive Officer
Anocca

Day 1 – Track A – Evening

4:30 pm | Integrated Target Discovery & TCR Generation Pipelines for TCR-Modified Cell Therapies

Maurizio Chiriva Internati
President, Chief Executive Officer, Chairman & Founder
Kiromic BioPharma

Benjamin Rengstl
Director Immunoreceptor Therapy & Medical Expert Clinical Development
BioNTech Cell & Gene Therapies & BioNTech SE

Workshop – Track B – Afternoon

12:00 pm | Workshop E: BNT211: A Phase 1/11 Trial to Evaluate Safety & Efficacy of CLDN6 CAR-T & CARVas Based In Vivo Expansion to Improve Treatment of Patients with CLDN6+ Advanced Solid Tumours

Giulia Casorati
Head of Experimental Immunology Unit
San Raffaele Scientific Institute

Day One

Tuesday 25th February 2020

8:30 am | Antigen-Specific Targeting of Tumours Across MHC Barriers

Workshop - Track A - Evening

3:00 pm | Workshop C: Antigen-Specific Targeting of Tumours Across MHC Barriers

Emily Titus
Vice President, Process Sciences
Notch Therapeutics

Christopher Baldwin
Chain Director, Cell & Gene Therapy
GSK

Day 1 – Track C – Morning

11:00 am | Paving the Future of Supply Chain & Logistics with Digitalisation & Automation

Leah Sibener
Co-Founder, Head of Therapeutic Discovery
3T Biosciences

Workshop – Track B – Evening

3:00 pm | Workshop F: Supercharging Development of Innovative Platforms for Identification & Validation of Novel Targets Beyond CD19

Kate Rochlin
Chief Operating Officer
IN8bio

Day Two

Wednesday 26th February 2020

5:30 pm | Chair’s Closing Remarks

4:45 pm | Novel Gamma-Delta CAR-T approaches for systemic delivery in Solid Tumors

Laura Pierce
Biomedical Engineer
NIST

Workshop – Track C – Afternoon

12:00 pm | Workshop H: Advancing Measurement Methods to Improve Confidence in Characterising CTPs

Richard Boyd
Chief Scientific Officer
Cartherics

Focus Day - Track B - Morning

10:00 am | iPSC - A Uniquely Renewable Source of CAR-NK Cells

Nicholas Boyd
Chief Technology Officer
Cartherics

Day 2 - Track C - Evening

3:45 pm | Allogenic Solid Tumor Immunotherapy using iPSCDerived Gene-Edited iNK Cells

Eric Von Hofe
Chief Executive Officer
AffyImmune

Stanley Frankel
Chief Medical Officer
Cytovia

Day 2 - Track C - Afternoon

1:45 pm | Exploring the Potential of Combining Engineered iPSC NK Cells with NK cell Engagers and the Future of Cell Therapies

Focus Day - Track B - Afternoon

12:00 pm | Exploring the Potential of Combining Engineered iPSC NK Cells with NK cell Engagers & the Future of Cell Therapies

Mythili Koneru
Chief Medical Officer
Marker Therapeutics

Day Two

Wednesday 26th February 2020

8:45 am | Allogeneic Multi-Tumour-Associated Antigen-Specific T-Cell Therapy

Mubin Tarannum
Post-Doctoral Researcher
Dana-Farber Cancer Institute

Day 2 - Track C - Evening

4:15 pm | Memory-Like NK Cell CARs for Mesothelin Expressing Solid Tumours

Focus Day - Track B - Evening

1:30 pm | Memory-Like NK Cell CARs for Mesothelin Expressing Solid Tumours

Michael Kchlinsky
Co-Founder
Carisma Therapeutics

Focus Day - Track B - Evening

2:30 pm | Development of CT-0508, a First-in-Class CAR-M, for Solid Tumour Immunotherapy

Qasim Rafiq
Senior Lecturer & Associate Professor - Cell & Gene Therapy Bioprocessing
University College London

Day 1 – Track C – Afternoon

3:00 pm | Panel Discussion: Creating the Therapies of Tomorrow with Large Scale Production of Off-the-Shelf Products

1:30 pm | Process Intensification and Scalable Manufacturing Strategies for CAR-T Production

Marko Radic
Associate Professor
The University of Tennessee Health Science Center

Focus Day - Track A - Evening

1:30 pm | Roads to Cell Therapy in Autoimmune Diseases

Scott Kitchen
Director & Associate Professor – Medicine
UCLA

Day 2 - Track B - Evening

4:15 pm | Engineering TCR & CAR-T Cells Through Hematopoietic Stem Cells

Focus Day - Track A - Afternoon

12:00 pm | Engineering TCR & CAR-T Cells Through Hematopoietic Stem Cells

Maja Buerdek
Director Translational Medicine
Medigene

John Maher
Chief Scientific Officer
Leucid Bio

Day 1 - Track A - Morning

12:00 pm | CAR-T Cell Immunotherapy of Solid Tumours: Parallel Learning from the Clinic & Lab

Chris Bond
Senior Vice President Preclinical & Translational Sciences
Notch Therapeutics

Cedrik Britten
Chief Medical Officer
Immatics

Day 1 – Track B – Morning

11:00 am | Driving Clinical Activity of TCR-T Cells in the Challenging Solid Tumour Setting

Day One

Tuesday 25th February 2020

9:00 am | Industry Leaders’ Fireside Chat - Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches

Peter Olagunju
Chief Technical Officer
TCR2 Therapeutics

Hong Ma
Senior Vice President, Clinical Development
CARsgen Therapeutics

Maria Castellà
Research Associate, Immunotherapy Unit
Hospital Clinic de Barcelona

Rajiv Khanna
Professor, Senior Scientist, Head Department of Immunology
QIMR Berghofer Medical Research Institute

Focus Day - Track A - Evening

2:30 pm | “Off-the-Shelf” Allogeneic CAR & TCR Cell Therapies for Virus-Associated Diseases

David Fontana
Chief Business & Strategy Officer
Umoja BioPharma

Day 1 – Track A – Afternoon

3:00 pm | Panel Discussion: Changing the Face of Cell Therapies with In Vivo Gene Engineering

2:30 pm | Attacking Solid Tumours with an Integrated Approach of Universal Tumour Tags & In Vivo Transduced CARs

Hannes Iserentant
Senior Director R&D and IP
Celyad

Day 1 – Track C – Afternoon

3:00 pm | Panel Discussion: Creating the Therapies of Tomorrow with Large Scale Production of Off-the-Shelf Products

2:30 pm | Building on Non-Gene Edited Approaches to Develop Allogeneic, Off-The-Shelf CAR-T Cells

Roddy O’Connor
Research Assistant Professor
Center for Cellular Immunotherapies, UPenn School of Medicine

Day 2 - Track A - Afternoon

Yihong Yao
Chief Scientific Officer
CBMG

Jak Knowles
Chief Executive Officer
Affini-T Therapeutics

Workshop - Track A - Afternoon

12:00 pm | Workshop B: Armouring T-Cells to Overcome the Tumour Microenvironment for TCR Therapies in Solid Tumours

Ali Mohamed
Vice President of CMC
Immatics

Day 1 – Track C – Evening

6:00 pm | Roundtable Discussion- Manufacturing Innovations to Improve Robustness of T cell Therapies

Day 2 - Track C - Morning

11:45 am | Developing Next-Generation TCR-T Therapies by CD8 Co-Expression

Workshop - Track C - Morning

9:00 am | Workshop G: Manufacturing Innovations to Improve Robustness of T-Cell Therapies

Lawrence Lamb
Chief Scientific Officer
IN8bio

Day 2 - Track B - Morning

10:45 am | Maintaining Both Innate Killing & Specific Targeting of Heterogeneous Tumours with Chemotherapy-Resistant Chlorotoxin CAR-T Cells

Day Two

Wednesday 26th February 2020

8:05 am | Chair’s Opening Remarks

Blake Aftab
Chief Scientific Officer
Adicet Bio

Day 1 – Track B – Evening

6:00 pm | Driving Development of Allogeneic Cell Therapies and CAR-T with Novel Signalling Technologies

Marc Martinez-Llordella
Founder & Vice President Biology
Quell Therapeutics

Day 2 - Track B - Evening

3:45 pm | Use of Engineered Regulatory T-Cells to Induce Immunologic Tolerance: Path to the Clinic

Focus Day - Track A - Afternoon

11:30 am | Use of Engineered Regulatory T-Cells to Induce Immunologic Tolerance: Path to the Clinic

Haig Aghajanian
Vice President of Research
Capstan Therapeutics

Focus Day - Track A - Morning

10:30 am | CAR-T Cell Therapy for the Treatment of Fibrotic Conditions

Workshop - Track A - Morning

9:00 am | Workshop A: In Vivo Production of Functional CAR-T Cells by mRNA Targeted Lipid Nanoparticles

Sylvain Simon
Postdoctoral Fellow
Fred Hutchinson Cancer Research Center

Rudy Gonzalez
Executive Director of Stem Cell Therapeutics
Caribou Biosciences

Day 2 - Track C - Afternoon

2:15 pm | Induced Pluripotent Stem Cell-Derived Natural Killer Cells for the Treatment of Solid Tumours

Focus Day - Track B - Afternoon

11:30 am | Induced Pluripotent Stem Cell-Derived Natural Killer Cells for the Treatment of Solid Tumours

Steven Kanner
Chief Scientific Officer
Caribou Biosciences

Day 1 – Track B – Afternoon

2:30 pm | Next Generation Allogeneic CAR-T Cell Therapies for Hematologic Malignancies

Day 1 – Track B – Evening

4:30 pm | Roundtable Discussion: Exploring Safety, Function and Potency of Allogeneic CAR-T Cells

Jan Davidson-Moncada
Chief Medical Officer
Wugen

Day 2 - Track B - Afternoon

2:45 pm | A Phase 1/2 Dose-Escalation & Dose-Expansion Study of the Safety & Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / Acute Lymphoblastic Lymphoma (LBL)

Remus Vezan
Chief Medical Officer
CERo Therapeutics

Lucia Mori
Founding Chief Scientific Officer
Matterhorn Biosciences

Day One

Tuesday 25th February 2020

8:30 am | Antigen-Specific Targeting of Tumours Across MHC Barriers

Workshop - Track A - Evening

3:00 pm | Workshop C: Antigen-Specific Targeting of Tumours Across MHC Barriers

Vijay Reddy Peddareddigari
Chief Research & Development Officer
Tmunity Therapeutics

Day 1 – Track B – Afternoon

1:30 pm | Overcoming CAR-T Toxicity with Next Generation T-Cell Reprogramming

Peggy Sotiropoulou
Chief Scientific Officer
T-knife Therapeutics

Day 1 - Track A - Morning

11:00 am | A Next Generation TCR & Epitope Discovery Platform for the Development of Engineered TCR Therapies for Solid Tumours

Day One

Tuesday 25th February 2020

9:00 am | Industry Leaders’ Fireside Chat - Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches

8:20 am | Chair’s Opening Remarks

Tina Albertson
Chief Medical Officer, Head of Development
Lyell Immunopharma

Day 1 – Track C – Evening

5:30 pm | Improving T-Cell Function with Epigenetic & Genetic Reprogramming to Improve Cell Therapy Outcomes in Solid Tumours

Workshop – Track C – Evening

3:00 pm | Workshop I: Improving T-Cell Function with Epigenetic & Genetic Reprogramming to Improve Cell Therapy Outcomes in Solid Tumours

Namir Hassan
Chief Executive Officer
Zelluna Immunotherapy

Day 2 - Track A - Morning

10:45 am | TCR-NK: A Novel Treatment Paradigm For The Treatment of Solid Cancer

Pascal Touchon
President & Chief Executive Officer
Atara Biotherapeutics

Focus Day - Track A - Morning

10:00 am | Allogeneic vs Autologous Cell Therapies: CAR-T & Beyond

Nicholas Clarkson
Vice President and Head of Platform Research
Oxford Biomedica

Day 2 - Track C - Morning

12:15 pm | Advances in Lentiviral Technology and Manufacturing Processes

Emily Wilkinson
Adoptive Cell Lead Research Analyst
Beacon

Day 2 - Track B - Morning

11:15 am | A Landscape Overview of CAR-T Cell Therapy

Justyna Ogonek
Senior Scientist
Medigene

Day 1 – Track A – Evening

6:00 pm | Identifying Peptide Targets for TCR-Ts Derived from Non-Coding RNA Sequences

Ali Shariat
Senior Director, Business Development
Syneos Health

Rayna Patel
Co-Founder & CEO
Vinehealth

Dr Rayna Patel is a medical doctor & neuroscientist with an MPhil in Translational Medicine. She has extensive experience in academia (Cambridge, Harvard, MIT, Columbia) and was an Associate Fellow of Clare Hall College, Cambridge. Rayna has subsequently held strategic & commercial roles in government policy, tech startups & the Cabinet Office’s Nudge Unit, where she used behavioural science to rewire patient behaviours through digital products. She is currently CEO and Co-Founder of Vinehealth, a digital platform using a combination of behavioural science and AI to improve the quality of life and survival of cancer patients, whilst generating crucial real-world data to better inform healthcare delivery and drug development.

Day 1 – Track B – Afternoon

3:00 pm | Next-Gen Cell Therapies- Listening and Engaging with Patient Perspectives as an Essential Element in Clinical Trials

Houria Bachtarzi
Associate Director, Regulatory - Gene and Cell Therapies
ProPharma Group

Day 1 – Track B – Evening

5:00 pm | Navigating the Challenges and Safety Considerations for Next-Generation Cell Therapies

Taylor Jensen, PhD
VP, Head of Labcorp Oncology
Labcorp Oncology

Payal Roychoudhury, PhD, MBA
Field Application Specialist, Central Europe
ScaleReady

Mark Harris
Senior Scientist
Autolus

Day 1 – Track C – Morning

12:00 pm | Autologous CAR-T Cell Automation and Certification Time

Sara Padrell
Business Development Director
Akron Bio

Day 1 – Track C – Morning

11:30 am | Akron’s New Line of Closed System Solutions™ & the Production of Next Generation Cell-Based Immunotherapies

Robert Newman
Chief Scientific Officer
FUJIFILM Irvine Scientific

Day 1 – Track A – Afternoon

2:00 pm | 3 Key Factors in Cell Cryopreservation that Impact the Manufacturability of Cell & Gene Therapies

Peter Djali
Manager, Cell Avidity/Immuno-Oncology Division
LUMICKS

Day 1 - Track A - Morning

11:30 am | Tumour-Effector Cell Avidity is a Key Driver for Cellular Therapy Efficacy

Luca Gattinoni
Professor, Chair for Functional Immune Cell Modulation
Leibniz Institute for Immunotherapy

Day 1 – Track A – Evening

5:00 pm | Reprogramming T Cell Fate and Antitumor Function by MicroRNA Therapeutics

Toni Cathomen
Professor of Cell and Gene Therapy, Director, Institute for Transfusion Medicine and Gene Therapy,Scientific Director, Center for Chronic Immunodeficiency
University of Freiburg

Day 1 – Track C – Evening

5:00 pm | Advances in Non-Viral T-Cell Engineering in Clinical Manufacturing

Mark Throsby
COO, CSO
Gadeta

Day 2 - Track A - Morning

11:45 am | Harnessing Natural gd T-cell Receptors (gd TCR) to Develop Effective Cellular Therapies for Solid Tumors

Brian Philip
Associate Director of Allogeneic Therapy
Triumvira Immunologics Inc

Day 2 - Track B - Afternoon

1:45 pm | Making Solid Tumour Immunotherapy Safer and More Accessible

Rudy Gonzalez
Executive Director of Stem Cell Therapeutics
Caribou Biosciences

Amanda Trent
PhD, Director of Assay Development
Accellix

Day 2 - Track C - Morning

11:15 am | Standardizing in-process QC with the Accellix Automated Flow Cytometry Platform.

Lynn Donald
Senior Project Director
Syneos Health , Novel and Emerging Therapies, Oncology

Day 1 – Track B – Afternoon

3:00 pm | Next-Gen Cell Therapies- Listening and Engaging with Patient Perspectives as an Essential Element in Clinical Trials

Sophie Papa
Chief Medical Officer
Enara Bio

Day 1 – Track B – Afternoon

3:00 pm | Next-Gen Cell Therapies- Listening and Engaging with Patient Perspectives as an Essential Element in Clinical Trials

Marvin Gee
VP of Target Discovery, Co-Founder
3T Biosciences

Day 2 - Track A - Evening

3:45 pm | Supercharging Development of Innovative Platforms for Identification and Validation of Novel Targets Beyond CD19

Natalia Denisova, MD, PhD
VP, Head of Medical Affairs
MphaR

Certified oncologist, experienced Medical Affairs professional with more than 15 years in Pharmaceutical Industry with a demonstrated history of preparation and leading successful launch in Oncology/OncoHematology and other therapeutic areas. Was leading international teams across more than 70 countries WW. In her current role Natalia provides the leadership to MphaR Clinical development team to support clinical trials in the most efficient way.

Day 1 – Track B – Afternoon

2:00 pm | How to Overcome the Recruitment Challenges in CAR-T cell Clinical Trials

Aaron K. Sato, Ph.D.
Chief Scientific Officer
Twist Bioscience

Day 2 - Track A - Morning

11:15 am | Writing the Future of Cell Therapies using the Twist Biopharma Library of Libraries

Chris Herring
VP Head of Discovery Research,
Adaptimmune

Day 2 - Track B - Afternoon

2:15 pm | Leveraging Clinical and Translational Insights from Next Generation SPEAR T-cells: Building a MAGE A4 T-Cell Therapy Franchise

Terry Fry
Senior Vice President, Head of T Cell Therapeutics
Sana Biotechnology, Inc.Institute

Day One

Tuesday 25th February 2020

9:30 am | Hypoimmune & In Vivo Delivery Platforms to Enable Off-The-Shelf CAR-T Cell Therapies

Peter Djali
Manager, Cell Avidity/Immuno-Oncology Division
Lumicks

Marco Rotondi
Project Leader – Process Development
Cellectis

Jakob Dupont
Executive Vice President, Head of Global Research & Development
Atara Biotherapeutics

Day 1 – Track B – Evening

5:30 pm | Accelerating Clinical Development of Off-the-Shelf Cell Therapy for Liquid and Solid Tumours

Melanie Rietenbach
Global Product Manager Immunology Engineered Cells
Miltenyi

Geoff Hodge
Chief Executive Officer
SOTIO US

Day 2 - Track A - Afternoon

1:45 pm | BOXR: A Platform for Improving T-Cell Performance in the Solid Tumour Microenvironment

Simone Steiner
Head, Technical Development and Manufacturing
Tigen Pharma

Day Two

Wednesday 26th February 2020

9:15 am | How to Overcome Apheresis Products Variability in Cell and Gene Therapy Manufacturing: Best Practices in Optimizing Cell Collection

Sara Lewandowski
Data Services Manager
Terumo Blood and Cell Technologies

Day Two

Wednesday 26th February 2020

9:15 am | How to Overcome Apheresis Products Variability in Cell and Gene Therapy Manufacturing: Best Practices in Optimizing Cell Collection

Mourad Ferhat
EMEA Product Manager
Isoplexis

Dr Richard Harbottle
Head of DNA Vector Research
German Cancer Research Centre (DKFZ)

Day 1 – Track B – Morning

11:30 am | Next-Generation DNA NanoVectors - An Alternative Vector Platform for the Safe, Rapid, and Persistent Manufacture of Recombinant T cells for Autologous T Cell Immunotherapy

Christopher Heery
Chief Medical Officer
Arcellx

Day 2 - Track B - Morning

11:45 am | ARC-sparX : A Modular & Universal Cell Platform

Cécile Bauche
Chief Scientific Officer
Ixaka

Day 1 – Track A – Afternoon

3:00 pm | Panel Discussion: Changing the Face of Cell Therapies with In Vivo Gene Engineering

1:30 pm | A Nanotechnology-Based In Vivo Gene Delivery Platform Allowing the In Vivo Targeting & Transduction of T-Cells for Haematological Malignancies & Beyond

Day 1 – Track C – Evening

4:30 pm | Bioproduction Challenges to Bring In Vivo Car-T into the Clinic

Hinrich Abken
Regensburg University
RCI Regensburg Center for Interventional Immunology

Samantha O’Hara
Allogeneic Research Lead
Umoja Biopharma

Day 2 - Track C - Afternoon

Dolores J. Schendel
Chief Executive Officer & Chief Scientific Officer
Medigene AG

Sven Killi
Chief Executive Officer
Antion Biosciences SA

Day 2 - Track A - Afternoon

2:45 pm | Multiplex Gene Engineering with miCAR – Moving Beyond Editing to Create Next Generation Allogeneic Cell Therapies

Adrian Bot, MD, PhD
Chief Scientific Officer and Executive Vice President, R&D
Capstan Therapeutics

Day One

Tuesday 25th February 2020

9:00 am | Industry Leaders’ Fireside Chat - Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches

Day Two

Wednesday 26th February 2020

5:00 pm | Towards Next Generation CAR Therapy Including In Vivo Programming of Immune Cells & Non-Oncology Indications

Workshop - Track A - Morning

9:00 am | Workshop A: In Vivo Production of Functional CAR-T Cells by mRNA Targeted Lipid Nanoparticles